TransCode Therapeutics, Inc. (RNAZ) — Financial statements
Income statement, balance sheet, and cash flow for TransCode Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.53↑3.5% | 0.52↑424.1% | 0.10↑132.2% | 0.04 | |
| Gross Profit | 0.00↑100.0% | -0.53↓3.5% | -0.52↓424.1% | -0.10↓132.2% | -0.04 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↑39.6% | 10↓21.6% | 12↑19.9% | 10↑271.6% | 3 | |
| General & Administrative Expenses | 6 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑4.7% | 6↓17.0% | 7↓20.4% | 8↑148.5% | 3 | |
| Other Expenses | 9 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 28↑85.0% | 15↓20.0% | 19↑1.8% | 19↑203.9% | 6 | |
| Total Costs & Expenses | 28↑78.7% | 16↓19.4% | 19↑4.0% | 19↑203.5% | 6 | |
| Operating Results | ||||||
| Operating Income | -28↓78.7% | -16↑19.4% | -19↓4.0% | -19↓203.5% | -6 | |
| Depreciation & Amortization | 0.11↓78.7% | 0.53↑3.5% | 0.52↑424.1% | 0.10↑132.2% | 0.04 | |
| EBITDA | -34↓111.9% | -16↑9.9% | -18↓2.9% | -17↓160.5% | -7 | |
| EBIT | -34↓105.8% | -17↑9.5% | -18↓5.3% | -18↓160.3% | -7 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.07↑377.8% | -0.03↑48.4% | -0.05↑99.7% | -18↓18484.2% | -0.09 | |
| Interest Income | 0.08↑11478.7% | 0.00↓87.1% | 0.01↓74.1% | 0.02↑2973.8% | 0.00 | |
| Interest Expense | 0.01↓75.3% | 0.03↓52.0% | 0.06↓99.7% | 18↑18375.8% | 0.10 | |
| Non-Operating Income | 6↑504.1% | 1↑215.0% | -0.93↑15.7% | -1↓284.3% | 0.60 | |
| Other Income / Expenses | -6↓489.9% | -1↓225.4% | 0.87↓20.7% | 1↑259.0% | -0.69 | |
| Income Before Tax | -34↓105.5% | -17↑9.7% | -19↓5.6% | -18↓156.7% | -7 | |
| Income Tax Expense | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -35↓106.9% | -17↑9.7% | -19↓5.6% | -18↓156.7% | -7 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -35↓106.9% | -17↑9.7% | -19↓5.6% | -18↓156.7% | -7 | |
| Bottom-Line Net Income | -36↓116.5% | -17↑9.7% | -19↓5.6% | -18↓156.7% | -7 | |
| EPS (Basic) | -52.59↓11.6% | -47.14↑98.6% | -3,453.65↑95.3% | -73,187.37↓11194.3% | -648.00 | |
| EPS (Diluted) | -52.59↓11.6% | -47.14↑98.6% | -3,453.53↓219.8% | -1,080.00↓66.7% | -648.00 | |
| Weighted Average Shares | 0.69↑93.7% | 0.36↑6465.5% | 0.01↓66.6% | 0.02↑54.0% | 0.01 | |
| Weighted Average Diluted Shares | 0.69↑93.7% | 0.36↑6465.5% | 0.01↓66.6% | 0.02↑54.0% | 0.01 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.